Advertisement

Topics

FDA grants orphan drug status to Ocugen’s OCU300 for oGVHD treatment

19:00 EDT 10 Aug 2017 | Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for Ocugen’s OCU300 (brimonidine tartrate) to treat patients with ocular graft versus host disease (oGVHD).

Original Article: FDA grants orphan drug status to Ocugen’s OCU300 for oGVHD treatment

NEXT ARTICLE

More From BioPortfolio on "FDA grants orphan drug status to Ocugen’s OCU300 for oGVHD treatment"

Quick Search
Advertisement
 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...